<DOC>
	<DOCNO>NCT00889980</DOCNO>
	<brief_summary>There significant need develop new effective way treat melanoma decrease patient morbidity mortality . This protocol intend collect process portion ( &lt; 20 % node ) lymph node melanoma patient undergoing routine surgical SLN resection : SLN ( ) 1 adjacent non-SLN ( ) plan study . In addition , blood drawn pre study visit ( serum peripheral blood mononuclear cell ) appropriate lineage control tissue collect . Material already-indicated plan procedure part standard medical care use . The main goal study properly collect process material analyze explore molecular feature melanoma biological sample .</brief_summary>
	<brief_title>Melanoma Molecular Profiling Analysis</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Primary melanoma follow Breslow thickness stage ≥ 2 mm ulceration , T3b ≥ 4 mm without ( T4a ) ( T4b ) ulceration Patients biopsied tumor widely resect also eligible study accord abovespecified criterion tumor thickness stage . Age 12 year old . Patients must document hemoglobin level 10g/dL high . This drawn day consent , document previous visit within past 30 day Subjects must provide write , informed consent prior study procedure : collection blood LN tissue specimens protocol . Serious illness may consider contraindication surgery determine physician investigator . If subject clear surgery clinically indicate ( wide excision primary melanoma sentinel lymph node biopsy ) , subject would eligible . Any significant psychiatric disease , medical intervention , condition , opinion Principal Investigator CoInvestigators , could prevent adequate informed consent compromise participation clinical trial . Active infection antibiotic within oneweek prior study Systemic steroid immunosuppressive therapy administer 10 day within 4 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>